Literature DB >> 21572851

Prevalence of anaemia and immunological markers among ghanaian HAART-naïve HIV-patients and those on HAART.

W K B A Owiredu1, L Quaye, N Amidu, O Addai-Mensah.   

Abstract

BACKGROUND: Highly active antiretroviral therapy (HAART) for people living with HIV/AIDS (PLWHA) has been generally accepted as the gold standard for the management of HIV patients but conflicting reports about the ability of HAART to improve upon the quality of life of HIV patients has cast doubts over the efficacy and the need for therapy.
OBJECTIVE: This study was conducted to assess the efficacy and ability of HAART to resolve immunological and haematological abnormalities in HIV infected patients, existent sex variations in immunological and haematological parameters and CD4 predictive ability of the study parameters.
METHODS: A total of 442 PLWHA consisting of 166 patients on HAART (28 males and 138 females) and 276 HAART-naïve patients (76 males and 200 females) were recruited for this study. Complete haemogram, immunological analysis (CD4 & CD3) and weight were measured for all the patients.
RESULTS: HAART patients were older and heavier than their naïve counterparts. The incidence of anaemia (Hb less or equal to 10.5 (63%) and PCV < 30% (37.6%)) and lymphopoenia (16.7%) in HAART-naïve patients was significantly higher compared to their counterparts on HAART (46%, 15.2% and 5.3%) respectively. 70% of HAART-naïve females had anaemia in comparison to 44% in HAART-naïve males (P = 0.0001). The likelihood of developing microcytic hypochromic anaemia in HAART-naïve patients was 5 times more compared to those on HAART (P = 0.0002). Total lymphocyte count, haemoglobin, lymphocyte count and weight were significant predictors of CD4 counts and TLC values between 1.0 - 2.0 k µL(-1) was a significant predictor of CD4 <200 cells mm(-3).
CONCLUSION: HAART has the capability of reducing the incidence of anaemia and lymphopoenia which are associated with disease progression and death in HIV infected patients. Total lymphocyte count, haemoglobin and weight could also serve as useful predictive tools in the management and monitoring of HIV infected patients in resource limited settings.

Entities:  

Keywords:  Antiretroviral; CD4; Lymphocyte; TLC; WHO/ACTG

Mesh:

Year:  2011        PMID: 21572851      PMCID: PMC3092327     

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN: 1680-6905            Impact factor:   0.927


  35 in total

1.  Predicting CD4 count using total lymphocyte count: a sustainable tool for clinical decisions during HAART use.

Authors:  D Mkaya Mwamburi; Mayurika Ghosh; Jim Fauntleroy; Sherwood L Gorbach; Christine A Wanke
Journal:  Am J Trop Med Hyg       Date:  2005-07       Impact factor: 2.345

2.  Effect of a liquid nutritional supplement on viral load and haematological parameters in HIV-positive/AIDS patients.

Authors:  O O Oguntibeju; W M J Van Den Heever; F E Van Schalkwyk
Journal:  Br J Biomed Sci       Date:  2006       Impact factor: 3.829

Review 3.  Cobalamin deficiency in patients infected with the human immunodeficiency virus.

Authors:  A F Remacha; J Cadafalch
Journal:  Semin Hematol       Date:  1999-01       Impact factor: 3.851

4.  Virulent HIV strains?

Authors:  M Tersmette; H Schuitemaker
Journal:  AIDS       Date:  1993-08       Impact factor: 4.177

5.  HIV-related thrombocytopenia.

Authors:  M Pechère; K Samii; B Hirschel
Journal:  N Engl J Med       Date:  1993-06-17       Impact factor: 91.245

6.  Anemia and survival in HIV infection.

Authors:  R D Moore; J C Keruly; R E Chaisson
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998-09-01

Review 7.  Hematologic complications of HIV infection.

Authors:  Elaine Sloand
Journal:  AIDS Rev       Date:  2005 Oct-Dec       Impact factor: 2.500

Review 8.  Hematologic complications of human immunodeficiency virus infection and the acquired immunodeficiency syndrome.

Authors:  T E Coyle
Journal:  Med Clin North Am       Date:  1997-03       Impact factor: 5.456

9.  Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group.

Authors:  A Mocroft; O Kirk; S E Barton; M Dietrich; R Proenca; R Colebunders; C Pradier; A dArminio Monforte; B Ledergerber; J D Lundgren
Journal:  AIDS       Date:  1999-05-28       Impact factor: 4.177

10.  Correlation among total lymphocyte count, absolute CD4+ count, and CD4+ percentage in a group of HIV-1-infected South African patients.

Authors:  E van der Ryst; M Kotze; G Joubert; M Steyn; H Pieters; M van der Westhuizen; M van Staden; C Venter
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998-11-01
View more
  36 in total

1.  A Study of Alternate Biomarkers in HIV Disease and Evaluating their Efficacy in Predicting T CD4+ Cell Counts and Disease Progression in Resource Poor Settings in Highly Active Antiretroviral Therapy (HAART) Era.

Authors:  K V Ramana; V Sabitha; Ratna Rao
Journal:  J Clin Diagn Res       Date:  2013-07-01

2.  A non-specific biomarker of disease activity in HIV/AIDS patients from resource-limited environments.

Authors:  Priyesh Bipath; Peter Levay; Steve Olorunju; Margaretha Viljoen
Journal:  Afr Health Sci       Date:  2015-06       Impact factor: 0.927

3.  Immuno-Haematological Abnormalities of HIV-Infected Patients Before and After Initiation of Highly Active Antiretroviral Therapy in the Antiretroviral Therapy Clinics of Six Health Facilities at Dessie Town, Northeast Ethiopia.

Authors:  Mihret Tilahun; Alemu Gedefie; Endris Ebrahim; Abdurahaman Seid; Abdurrahman Ali; Agumas Shibabaw; Melaku Ashagrie Belete; Mesfin Fiseha; Melkam Tesfaye; Hussen Ebrahim; Admasu Abera
Journal:  J Blood Med       Date:  2022-05-11

4.  Prevalence of anaemia and the associated factors among hospitalised people living with HIV receiving antiretroviral therapy in Southwest China: a cross-sectional study.

Authors:  Guiying Cao; Hai Long; Yuedong Liang; Jue Liu; Xiaoxin Xie; Yanhua Fu; Juan He; Su Song; Siqi Liu; Manna Zhang; Yu Wu; Yaping Wang; Min Du; Wenzhan Jing; Jie Yuan; Min Liu
Journal:  BMJ Open       Date:  2022-07-18       Impact factor: 3.006

5.  HIV-associated anemia after 96 weeks on therapy: determinants across age ranges in Uganda and Zimbabwe.

Authors:  Devan Jaganath; A Sarah Walker; Francis Ssali; Victor Musiime; Francis Kiweewa; Cissy Kityo; Robert Salata; Peter Mugyenyi
Journal:  AIDS Res Hum Retroviruses       Date:  2014-02-07       Impact factor: 2.205

6.  Hematological Abnormalities of Adult HIV-Infected Patients Before and After Initiation of Highly Active Antiretroviral Treatment at Debre Tabor Comprehensive Specialized Hospital, Northcentral Ethiopia: A Cross-Sectional Study.

Authors:  Shewaneh Damtie; Lemma Workineh; Teklehaimanot Kiros; Tahir Eyayu; Tegenaw Tiruneh
Journal:  HIV AIDS (Auckl)       Date:  2021-05-04

Review 7.  Current practices in laboratory monitoring of HIV infection.

Authors:  Madhu Vajpayee; Teena Mohan
Journal:  Indian J Med Res       Date:  2011-12       Impact factor: 2.375

8.  Prevalence and correlates of anemia among HIV infected patients on highly active anti-retroviral therapy at Zewditu Memorial Hospital, Ethiopia.

Authors:  Muluken Assefa; Woldaregay Erku Abegaz; Aster Shewamare; Girmay Medhin; Mulugeta Belay
Journal:  BMC Hematol       Date:  2015-04-30

9.  Development of Severe Anemia and Changes in Hemoglobin in a Cohort of HIV-Infected Ugandan Adults Receiving Zidovudine-, Stavudine-, and Tenofovir-Containing Antiretroviral Regimens.

Authors:  Rosalind Parkes-Ratanshi; David Katende; Jonathan Levin; Katie Wakeham; Grosskurth Heiner; Anatoli Kamali; David G Lalloo
Journal:  J Int Assoc Provid AIDS Care       Date:  2014-11-25

10.  Prevalence, severity, and related factors of anemia in HIV/AIDS patients.

Authors:  Mohsen Meidani; Farshid Rezaei; Mohammad Reza Maracy; Majid Avijgan; Katayoun Tayeri
Journal:  J Res Med Sci       Date:  2012-02       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.